Jonathan How

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J. Levis, Mehdi Hamadani, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 185 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia

Jonathan How, Mark D. Minden, Brian Leber et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 42 citations · Full text

Medicine, Oncology, Pharmacology +14

Influence of FLT3‐internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate‐risk karyotype acute myeloid leukemia

Jonathan How, Jenna Sykes, Vikas Gupta et al. · Cancer · 2012 · 40 citations · Full text

Life Sciences, Hematology, Molecular Genetics +14

Factors affecting discharge destination following lung transplantation

Min Tang, Nadir Mawji, Samantha Chung et al. · Clinical Transplantation · 2015 · 15 citations

Medicine, Surgery, Pulmonary Function Testing +9

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra et al. · Blood · 2022 · 14 citations

Medicine, Oncology, Pharmacology +10